(Translated by https://www.hiragana.jp/)
Home Page - IPWatchdog.com | Patents & Intellectual Property Law
Updated WHO Pandemic Accord Retains Commitments for Non-Exclusive Licensing and Royalty Waivers

On April 19, the World Health Organization (WHO) released an updated draft proposal of an international agreement on the global response to future pandemics. While the WHO pandemic agreement has been met with widespread support from many of the international agency’s member nations, including the United States, it retains provisions limiting intellectual property (IP) rights that have encouraged opposition from lawmakers and pharmaceutical innovators alike.

The SEP Couch: Lyse Brillouet on Managing SEPs and Open Standards

Lyse Brillouet has been the Chief Intellectual Property Officer and Senior Vice-President, Licensing, for the Orange Group since 2018. In the latest episode of The SEP Couch, Brillouet describes why intellectual property (IP) matters within the Orange Group, which has over 130,000 employees worldwide. IP for Orange is an important outcome of various research and development projects. Orange is a technology company, with its main objective being to bring technology and related service to its customers. In some cases, Brillouet must balance the monetization of IP and the promotion of a new standardized technology. One example of this is Orange’s strategy regarding patent pools.

FTC Approves Final Rule to Ban All New Non-Compete Agreements in 3-2 Vote

The U.S. Federal Trade Commission today voted in a Special Open Commission Meeting to publish and approve a final version of the January 2023 proposed rule that would ban employers from using clauses for their employees. Today’s rule allows existing non-competes to remain in force for senior executives but bans new non-competes for all workers and makes existing non-competes for all other workers unenforceable after the effective date, which is 120 days after publication in the Federal Register.

The Briefing: Tennessee’s ELVIS Act – Is This Attempt to Protect Musicians (and Record Labels) in the AI Era Enforceable?

Tennessee’s recent legislative move, the ELVIS Act (Ensuring Likeness, Voice, and the Image Security Act of 2024), has garnered attention for its efforts to address the challenges posed by artificial intelligence in the music industry. Signed into law on March 21, 2024, the ELVIS Act represents a big step by a state with a huge music industry presence to prevent the unauthorized use of artificial intelligence (AI)-generated musician soundalike content. But is it enforceable?

Unveiling The Untapped Potential of Brazil’s Solar Energy Market

Brazil, a country known for its abundant natural resources, is emerging as a significant player in the global renewable energy sector. Brazil has one of the highest levels of insolation in the world (ranging from 4.25 to 6.5 sun hours per day according to the Solar and Wind Energy Resource Assessment Project – (SWERA) and is therefore uniquely positioned to harness the power of the sun.

Chamber Appeals Decision to Deny Expedited FOIA Request on March-In Proposal

The U.S. Chamber of Commerce’s Global Innovation Policy Center (GIPC) has filed an appeal with the U.S. Department of Commerce, which denied the GIPC’s January 2024 Freedom of Information Act (FOIA) request seeking more detail about the working group behind the Biden Administration’s draft framework for considering the exercise of march-in rights. The proposed framework was published in the Federal Register in December 2023 by the Department of Commerce and the National Institutes for Standards and Technology (NIST) and included suggestions on whether and when to exercise “march-in rights” under the Bayh-Dole Act that would arguably significantly broaden the criteria for compulsory licensing of patented technology developed with federal funding.

SCOTUS Scraps Vanda’s Bid for Guidance on Obviousness Standard

The U.S. Supreme Court today denied a petition for certiorari seeking clarification from the Court on the proper standard for a showing of obviousness. Vanda Pharmaceuticals filed the petition following the U.S. Court of Appeals for the Federal Circuit’s (CAFC’s) May 2023 decision invalidating Vanda’s patent on a method of using the drug tasimelteon to treat Non-24-Hour Sleep-Wake Disorder. The CAFC came to its decision in part because the court said the disclosure of clinical trials was evidence that a person of ordinary skill in the art “would have had a reasonable expectation of success.” Vanda argued in its Supreme Court petition that a “predictable results” standard should be applied instead and maintained that the High Court said as much in KSR v. Teleflex.

Subscribe to IPWatchdog

This is the best way to stay informed. We send a daily roundup of our latest news, press releases, and events.

Get Email Updates